Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Sujal M. Patel Buys 7,405 Shares of Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUTGet Free Report) CEO Sujal M. Patel acquired 7,405 shares of Nautilus Biotechnology stock in a transaction that occurred on Tuesday, March 5th. The shares were purchased at an average price of $2.65 per share, for a total transaction of $19,623.25. Following the transaction, the chief executive officer now directly owns 10,021,893 shares in the company, valued at $26,558,016.45. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Nautilus Biotechnology Trading Up 2.4 %

NASDAQ:NAUT opened at $2.56 on Friday. The stock’s 50-day moving average is $2.85 and its 200-day moving average is $2.94. Nautilus Biotechnology, Inc. has a 1-year low of $2.13 and a 1-year high of $4.65. The stock has a market cap of $320.26 million, a P/E ratio of -4.92 and a beta of 1.17.

Nautilus Biotechnology (NASDAQ:NAUTGet Free Report) last posted its earnings results on Wednesday, February 28th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter in the prior year, the business earned ($0.11) EPS. As a group, equities analysts forecast that Nautilus Biotechnology, Inc. will post -0.72 EPS for the current year.

Institutional Trading of Nautilus Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG acquired a new position in shares of Nautilus Biotechnology in the fourth quarter worth approximately $26,000. Federated Hermes Inc. bought a new position in Nautilus Biotechnology during the 3rd quarter worth approximately $29,000. Axxcess Wealth Management LLC acquired a new position in shares of Nautilus Biotechnology in the 4th quarter worth approximately $30,000. Presidio Capital Management LLC acquired a new position in shares of Nautilus Biotechnology in the 4th quarter worth approximately $30,000. Finally, Shay Capital LLC bought a new stake in shares of Nautilus Biotechnology in the 4th quarter valued at $30,000. 35.90% of the stock is currently owned by institutional investors and hedge funds.

Nautilus Biotechnology Company Profile

(Get Free Report)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Recommended Stories

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.